Clinical Trials Logo

Clinical Trial Summary

Secondary Data Collection : To confirm the safety and effectiveness profiles under the actual medical practice of Vyndaqel in Japan. This study is conducted in accordance with the protocol even when Vynmac is used, and information the use of Vynmac during the observation period is also collected.


Clinical Trial Description

To comprehend information on the long-term safety (e.g., onset status of adverse reactions), etc. of patients who are treated with Vyndaqel for the treatment of transthyretin amyloid cardiomyopathy. When Vynmac is used, conduct the study to grasp information on safety (e.g., onset status of adverse reactions),etc. during the observation period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04108091
Study type Observational
Source Pfizer
Contact Pfizer CT.gov Call Center
Phone 1-800-718-1021
Email ClinicalTrials.gov_Inquiries@pfizer.com
Status Recruiting
Phase
Start date October 3, 2019
Completion date December 9, 2024

See also
  Status Clinical Trial Phase
Completed NCT02791230 - Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy Phase 3
Completed NCT01994889 - Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy Phase 3